tbuckley/cabot-search huggingface dataset:
Sir James Mackenzie's later Views on the Nature of Cardiac Action: Correction
Journal: BMJ (1927)

to be injurious Or dangerous to health shall be deemed to be a nuisance; or agaiust the employee uuder Section 58 of the sane Act andl the amendinig Act of 1907 for engagsing in au occupation connected with food, provided he knew that he was, in fact, suffering from (liphtheria aud did niot take proper precautions.But a local auithority proposing to go to court utnder any of the sections cited would probably be expected to prove, not merely negligence on the part of those concernied, but deliberate suppression of the facts, and also to show that its own officers, by visit, inquiry, and otherwise, lhad exercised due diligence to keep in touch with the progress of events at the bakery.THE ACTION OF IIROTROPINE.D. ROBERT ANDERSON (Erdington, Birmingham) writes: I would ask two questions with regard to the action of urotropiine.(1) -low can it act as an antiseptic in one part of the body only- in an acid medium and in another in an alkEaline one?(2) It its actioni in the first instance depends on its decposition by.aW acid, how does it escape decomposition by the hldrrchl6ric acid of th3e stomach?In the BRITISH MEDICAL JOURNAL, October 16th, 1926, Dr. Hurst states that urotropine has been provedto act as an antiseptic in alkaline bile.It is not generally'known that urotropine is a cause of d atitis in rubber workers.Such cases nearly always occur during kot weatbhJ, when the workers'perspire freely.The acids of the perspiration are supposed to decompose the urotropine.T The action of urotropine is rather,puzzle at present.
Human rabies reported for first time in almost two years
Authors: P. Gunby
Journal: JAMA (1981)

The recently reported human rabies case in Oklahoma City is the nation's first in nearly two years. However, it is the ninth (out of a total of 16) since 1966 in which there was no history of the patient's having been bitten by an animal. The patient, a 27-year-old man, died last month after nine days in a hospital. The diagnosis of rabies was made postmortem. At the Centers for Disease Control (CDC), Atlanta, officials say that when rabies is not diagnosed before death, it often is because there is an absence of hydrophobia or of a known history of exposure to the neurotropic virus. They say that the Oklahoma case "again shows that, for patients with encephalopathic illness of undetermined etiology, rabies should be considered." These officials also note that no human-to-human transmission of the rabies virus has been documented in the United States, except in the case of
"Pervitin."
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P01.21 * DIFFERENTIAL REGULATION OF TGF- -INDUCED, ALK-5-MEDIATED VEGF RELEASE BY SMAD2/3 VERSUS SMAD1/5/8 SIGNALING IN GLIOBLASTOMA
Authors: K. Seystahl, I. Tritschler, E. Szabo, G. Tabatabai, M. Weller
Journal: Neuro-Oncology (2014)

BACKGROUND: The transforming growth factor (TGF)-β and vascular endothelial growth factor (VEGF) pathways have been attributed a major role in the pathogenesis in glioblastoma, notably immunosuppression, migration and angiogenesis, but their interactions have remained poorly understood. METHODS: We characterized TGF-β pathway activity in nine long-term glioma cell lines (LTC) and 4 glioma-initiating cell lines (GIC) in relation to constitutive and exogenous TGF-β-induced VEGF release. Results were validated using TCGA transcriptomics data. RESULTS: Glioma cells exhibit heterogeneous patterns of constitutive TGF-β pathway activation reflected by phosphorylation not only of SMAD2 and SMAD3, but also SMAD1/5/8. Constitutive TGF-β pathway activity accounts for up to 69% of constitutive VEGF release which is positively regulated by SMAD2/3 and negatively by SMAD1/5/8 signaling in a cell line-specific manner. Exogenous TGF-β induces VEGF release in most cell lines, in a SMAD-dependent manner. There is no correlation between the fold induction of VEGF secretion induced by TGF-β compared to hypoxia. The role of SMAD5 signaling is highly context- and cell line dependent with a VEGF inhibitory effect at low TGF-β and pSMAD2 levels, and a stimulatory effect when TGF-β is abundant. DISCUSSION: TGF-β regulates VEGF release by glioma cells in an ALK-5-dependent manner involving SMAD2, SMAD3 and SMAD1/5/8 signaling. This crosstalk between the TGF-β and VEGF pathways may open up new avenues of biomarker-driven exploratory clinical trials focusing on the microenvironment in glioblastoma.
THE PROTECTIVE AND CURATIVE VALUE OF ANTISTREPTOCOCCUS SERUM.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lysozyme
Authors: Elliott F. Osserman
Journal: New England Journal of Medicine (1975)

Lysozyme, the virtually ubiquitous bacteriolytic enzyme discovered by Alexander Fleming over half a century ago,1 has been the subject of extensive physicochemical, physiologic and clinical investigation,2 but its full biologic implications are still incompletely defined. There is increasing evidence that this enzyme is a major constituent of both granulocytes and macrophages and presumably an important mediator of the complex and diverse functions of these cells. A critical question, however, is whether its functions are exclusively antibacterial or whether this low-molecular-weight, cationic protein also has specific enzymatic or polycation effects on polysaccharides of mammalian cells and their membranes. Some morphologic evidence . . .
American Journal of Public Health, New York
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Human Signal-Regulatory Protein Is Expressed on Normal, But Not on Subsets of Leukemic Myeloid Cells and Mediates Cellular Adhesion Involving Its Counterreceptor CD47
Authors: Martina Seiffert, Charles Cant, Zhengjun Chen, Irene Rappold, Wolfram Brugger, Lothar Kanz, Eric J. Brown, Axel Ullrich, Hans-Jörg Bühring
Journal: Blood (1999)
Gender Disparities in Procedure Use for Acute Myocardial Infarction in the United States, 1995-1997
Authors: Alain G Bertoni, Frederick L Brancati
Journal: Circulation (2001)

P03 Gender disparities in procedure use for acute myocardial infarction (AMI) have been well documented in selected populations in the 1980s and early 90s. However, little is known about recent trends in disparities in the general population. Therefore we conducted a series of cross-sectional analyses of data from the Nationwide Inpatient Sample for years 1995 through 1997 to compare rates of catheterization, angioplasty and coronary artery bypass grafting (CABG) performed prior to discharge for acute myocardial infarction in men vs. women. The NIS includes data (including demographics, diagnoses and procedures) on all discharges from over 900 representative civilian hospitals in 22 states. We identified 425,236 discharges with AMI (ICD9 code 410) as the first listed diagnosis during 1995-97. The cohort was 39% female (mean age 71.7) and 61% male (mean age 64.4). From 1995 to 97, catheterization rates increased in women (38.8% to 41.8%)and men (49.7% to 52.4%) as did rates of angioplasty (women 17.1% to 19.9%, men 23.0% to 26.6%) and CABG (women 8.3% to 8.7%, men 11.9% to 12.4%) After adjusting for age, race, and comorbidities, women were less than men to undergo catheterization in 1995 (odds ratio [OR] 0.85, 95% confidence interval [CI] 0.83-0.87), 1996 (OR 0.85, 95%CI 0.83-0.87), and 1997 (OR 0.87 95%CI 0.85-0.87). This gender disparity was even greater among adults aged 65 and older (adjusted OR 0.70, 95%CI 0.68-0.72 in 1995 and 96; and 0.71, 95%CI 0.69-0.72 in 1997). Women were also less likely to undergo CABG (adjusted OR 0.72, 95%CI 0.70-0.74 in 1995, 96 and 97). Among patients who underwent catheterization, women remained less likely to go on to CABG than men (adjusted OR 0.77, 95%CI 0.75-0.79). In contrast,women were only slightly less likely to undergo angioplasty (adjusted OR 0.93, 95%CI 0.91-0.94) and, once catheterized, were actually more likely to go on to angioplasty (adjusted OR 1.03, 95%CI 1.01-1.05). While procedure use for AMI is rising for men and women, these recent nationwide data suggest that women remain much less likely to undergo catheterization or CABG, but about equally likely to undergo angioplasty.
Treating HIV positive haemophiliacs with zidovudine.
Journal: BMJ (1988)

in Cambridge to pilot a low budget coronary prevention research project during the past two years.A simple computer program prestratifies each patient according to major risk factors and then randomises him or her firstly among possible antihypertensive groups and then among aspirin, fish oil, or "no treatment"-to ensure equal distribution of the latter groups for each of the antihypertensive agents.This project is now being expanded as a telephone randomisation service (as in the international study of infarct survival) to the rest of East Anglia, and we would be pleased to randomise any untreated hypertensive patient (diastolic pressure >90 mm Hg or systolic pressure > 160 mm Hg for three months).In our present state of ignorance we are -if we are honest-spinning a coin each time we start (or do not start) treatment in hypertension.If enough of us spin the same coin (telephone 0223 336743 for details) than we will find out not only whether we are overtreating hypertension but how to prevent coronary disease.
Cobalamin Radioassays
Authors: Richard B. Gilbert
Journal: JAMA (1981)

<h3>To the Editor.—</h3> Both the title and the conclusions of the recent article by Cohen and Donaldson (1980;244:1942) present a misconception. They (incorrectly) stated that commercial radioassay kits for cobalamin (vitamin B<sub>12</sub>) are chemically nonspecific and measure inactive cobalamin analogs. This statement was valid in 1978, the time of the initial investigation, but not currently. In this article, the lack of qualifying statements or date-limiting statements implies that the problem of 1978 still exists. Manufacturers were actually quick to attempt to correct this deficiency in their products, either by cobinamide blocking of "R" proteins or by purification of intrinsic factor by affinity chromatography. As stated in one manufacturer's package insert (<sup>57</sup>Co Vitamin B<sub>12</sub>Assay Kit With Purified B<sub>12</sub>Binder, package insert, Diagnostic Products Corp, Los Angeles, July 1980), these changes occurred as early as January 1979. The cobinamide-blocked kit used in the follow-up work reported may
Angkor Wat at Sunrise
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Acta Cytologica, Baltimore
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effects of swimming pool water on the cornea
Authors: J. R. Haag
Journal: JAMA (1983)

Eye examinations performed on 50 subjects immediately before and after swimming in a chlorinated pool showed that 34 subjects (68%) saw rainbows and/or halos around lights after swimming, a symptom indicating the presence of corneal edema. Forty-seven subjects (94%) had corneal epithelial erosions in a punctate or linear pattern demonstrated by fluorescein staining on slit-lamp examination. No subject experienced a measurable decrease in visual acuity. (<i>JAMA</i>1983;249:2507-2508)
Use of Single Course IV Fludarabine in Treatment of Hypocellular Bone Marrow (Aplastic Anaemia and MDS) Patients.
Authors: Shashikant J. Apte, Sujata U. Vaidya, Nikhil Shah, Seema Bhatwadekar, Akash Kalro, Bhavna Sayaji, Prashant Suryavanshi, Anjali J. Kelkar
Journal: Blood (2004)
Basophil Activation Test Discriminates Between Allergy and Tolerance Among Peanut Sensitized Children
Authors: Alexandra F. Santos, Natalia Bécares, Shih-Ying Wu, Suzana Radulovic, Alick Stephens, Victor Turcanu, George Du Toit, Gideon Lack
Journal: Journal of Allergy and Clinical Immunology (2013)
EXCELLENT APPOINTMENTS.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial
Authors: Philippe Moreau, Michel Attal, Lionel Karlin, Laurent Garderet, Thierry Facon, Margaret Macro, Lotfi Benboubker, Denis Caillot, Martine Escoffre, Anne-Marie Stoppa, Kamel Laribi, Cyrille Hulin, Gerald Marit, Jean Richard Eveillard, Florence Caillon, Caroline Bodet, Brigitte Pégourie, Veronique Dorvaux, Carine Chaleteix, Paul G. Richardson, Kenneth C. Anderson, Hervé Avet-Loiseau, Aurelie Gaultier, jean-Michel Nguyen, Benoit Dupas, Francoise Bodere
Journal: Blood (2015)
Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric or gastroesophageal junction cancer.
Authors: Tomohiro Nishina, Kohei Shitara, Satoru Iwasa, Shuichi Hironaka, Kei Muro, Taito Esaki, Taroh Satoh, Kensei Yamaguchi, Nozomu Machida, Anja von Heydebreck, Morihiro Watanabe, Toshihiko Doi
Journal: Journal of Clinical Oncology (2016)

168 Background: The programmed death-1 receptor (PD-1) and its ligand (PD-L1) are key therapeutic targets in the reactivation of the immune response against cancer. Avelumab* (MSB0010718C) is a fully human anti-PD-L1 IgG1 antibody being investigated in clinical trials. We report safety and clinical activity from this phase Ib dose expansion JAVELIN study (NCT01943461) of avelumab in Japanese patients (pts) with advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ) based on level of PD-L1 expression. Methods: GC/GEJ pts (ECOG performance status 0-1 at trial entry) received avelumab 10 mg/kg Q2W by IV infusion until confirmed progression, unacceptable toxicity, or withdrawal. Tumors were assessed every 6 wks (RECIST 1.1). Best overall response rate (ORR) and progression-free survival (PFS) were evaluated. Adverse events (AEs) were graded by NCI-CTCAE v4.0. PD-L1 expression on fresh tissue samples collected up to 6 mos prior to trial was assessed by immunohistochemistry using various cutoff criteria. Results: As of Mar 11 2015, 20 pts (18 GC, 2 GEJ) were treated with a median follow-up of 6 mos. Treatment-related treatment-emergent AEs (TR-TEAEs) of any grade occurred in 18/20 pts (90%); one patient (5%) reported a grade 3 TR-TEAE (alanine aminotransferase increase). There were no treatment-related deaths. Confirmed ORR was 15.0% based on 3 partial responses (PR) and the disease control rate (PR + stable disease) was 65.0%. PD-L1 expression was evaluable in 19 pts. Pts with PD-L1+ samples (n = 5 [26.3%]; ≥ 1% cutoff) showed a 40.0% ORR compared with 7.1% ORR in pts with PD-L1− samples (n = 14 [73.7%]; p= 0.155). Median PFS was 12.3 wks (95% CI: 3.1, ne) for PD-L1+ and 11.1 wks (6.0, 12.1) for PD-L1− ( ≥ 1% cutoff). PFS rate at 12 wks was 60.0% (95% CI: 12.6, 88.2) and 32.1% (10.2, 56.9) for PD-L1+ and PD-L1− pts, respectively. Conclusions: Single agent avelumab showed an acceptable safety profile and clinical activity in GC/GEJ pts. A trend of higher ORR and higher PFS rate was observed in PD-L1+ pts compared with PD-L1− in this small cohort. Further analysis is ongoing and expansion of this cohort to 40 pts is underway. *Proposed INN. Clinical trial information: NCT01943461.
Update: Multistate Outbreak of Listeriosis--United States, 1998-1999
Journal: JAMA (1999)

From early August 1998 through January 6, 1999, at least 50 illnesses caused by a rare strain of the bacterium Listeria monocytogenes, serotype 4b, have been reported to CDC by 11 states. Six adults have died and two pregnant women have had spontaneous abortions. Reported illness onset dates were during August 2-December 13, 1998. CDC and state and local health departments have identified the vehicle for transmission as hot dogs and possibly deli meats produced under many brand names by one manufacturer. This report updates the investigation of this outbreak.
Summary of the National Halothane Study
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal